These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 11900310)
1. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310 [TBL] [Abstract][Full Text] [Related]
2. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Greig NH; Lahiri DK; Sambamurti K Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181 [TBL] [Abstract][Full Text] [Related]
3. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Lane RM; Potkin SG; Enz A Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515 [TBL] [Abstract][Full Text] [Related]
4. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Giacobini E Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344 [TBL] [Abstract][Full Text] [Related]
5. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. Kamal MA; Klein P; Luo W; Li Y; Holloway HW; Tweedie D; Greig NH Neurochem Res; 2008 May; 33(5):745-53. PubMed ID: 17985237 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443 [TBL] [Abstract][Full Text] [Related]
7. Cholinesterases: new roles in brain function and in Alzheimer's disease. Giacobini E Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140 [TBL] [Abstract][Full Text] [Related]
8. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. Mushtaq G; Greig NH; Khan JA; Kamal MA CNS Neurol Disord Drug Targets; 2014; 13(8):1432-9. PubMed ID: 25345511 [TBL] [Abstract][Full Text] [Related]
9. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Ballard CG Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198 [TBL] [Abstract][Full Text] [Related]
10. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. Kamal MA; Al-Jafari AA; Yu QS; Greig NH Biochim Biophys Acta; 2006 Feb; 1760(2):200-6. PubMed ID: 16309845 [TBL] [Abstract][Full Text] [Related]
11. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer? Macdonald IR; Rockwood K; Martin E; Darvesh S J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642 [TBL] [Abstract][Full Text] [Related]
12. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525 [TBL] [Abstract][Full Text] [Related]
13. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. Kamal MA; Klein P; Yu QS; Tweedie D; Li Y; Holloway HW; Greig NH J Alzheimers Dis; 2006 Sep; 10(1):43-51. PubMed ID: 16988481 [TBL] [Abstract][Full Text] [Related]
14. TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology. Uddin MS; Kabir MT; Rahman MM; Mathew B; Shah MA; Ashraf GM J Pharm Pharmacol; 2020 Aug; 72(8):1001-1012. PubMed ID: 32149402 [TBL] [Abstract][Full Text] [Related]
15. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840 [TBL] [Abstract][Full Text] [Related]
16. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A; Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702 [TBL] [Abstract][Full Text] [Related]
17. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484 [TBL] [Abstract][Full Text] [Related]
19. Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. Li Q; Yang H; Chen Y; Sun H Eur J Med Chem; 2017 May; 132():294-309. PubMed ID: 28371641 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses. Kamal MA; Shakil S; Nawaz MS; Yu QS; Tweedie D; Tan Y; Qu X; Greig NH CNS Neurol Disord Drug Targets; 2017; 16(7):820-827. PubMed ID: 28176640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]